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Objectives: Significant differences have been reported in disease phenotype and severity of
systemic lupus erythematosus (SLE) presenting in different age groups. Most indicate a more
severe phenotype in juvenile-onset SLE (JSLE). There have been limited studies in older
patients and no large studies looking at SLE across all age groups. Methods: We assessed
the effect of age of onset of SLE on the clinical phenotype by analysing data from two large
UK cohorts (the UK JSLE Cohort and the UCLH SLE cohort). Results: A total of 924
individuals were compared (413 JSLE, 511 adult-onset SLE). A female preponderance was
present, but less pronounced at either end of the age spectrum. Arthritis was more common
with advancing age (93% vs 72%, p< 0.001), whereas renal disease (44% vs 33%, p¼ 0.001),
alopecia (47% vs 23%, p< 0.001) and aphthous ulcerations (39% vs 26%, p¼ 0.001) were
more common in the young. Neuropsychiatric lupus was less common in mature-onset SLE
(p< 0.01). JSLE was associated more commonly with thrombocytopenia (21% vs 15%,
p¼ 0.01), haemolytic anaemia (20% vs 3%, p< 0.001), high anti-dsDNA (71% vs 63%,
p¼ 0.009), Sm (22% vs 16%, p¼ 0.02) and RNP (36% vs 29%, p< 0.04) auto-antibodies.
Leucopenia increased with advancing age (p< 0.001). Mortality has been declining over recent
decades. However, death rates were substantially higher than the general population. The
standardized mortality ratio was 18.3 in JSLE and 3.1 in adult-onset SLE. Conclusion:
These data from the largest-ever direct comparison of JSLE with adult-onset SLE suggest
an aggressive phenotype of disease with a worse outcome in patients with JSLE and empha-
sizes the importance of careful follow-up in this population. Lupus (2016) 25, 1542–1550.
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Background
Systemic lupus erythematosus (SLE) is a severe,
complex, multi-system autoimmune rheumatic dis-
ease. It is most prevalent among women of child-
bearing age.1–3 Approximately 20% of cases begin
during childhood, usually after puberty,4–6 and
published data suggest a further 10–20% present
after the age of 50 years.7–9
Summaries of the main clinical and laboratory
features of juvenile-onset SLE (JSLE) have been
reported by several groups including our own,10
with most reports ﬁnding a severe phenotype with
a greater burden of steroids and immunosuppres-
sive treatment.10–15 However, previous comparison
studies generally assessed fewer than 100 JSLE
cases. Additionally few, if any, studies have
looked at SLE across the broader age groups
within the same study.
Previous studies have provided conﬂicting results
regarding the changes in clinical phenotype across
age groups. Most studies ﬁnd more renal disease
and more haematological involvement in JSLE.
However, for many other features including mor-
tality risk, neuropsychiatric lupus (NPSLE), sero-
sitis, arthritis and autoantibody proﬁles, reports are
conﬂicting. The reasons for the disparity are likely
to be multifactorial, with relatively small cohort
size, retrospective data collection and/or variability
in case deﬁnitions contributing to the diﬀerences.
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In this report we describe the eﬀect of age at
onset of SLE on the phenotypic manifestations by
assessing two large cohorts: the United Kingdom
(UK) JSLE Cohort Study and the University
College London Hospital (UCLH) cohort.
Methods
We combined two cumulative historical databases
to assess clinical and laboratory features and how
they related to age at onset of SLE. All patients
fulﬁlled the revised criteria for the classiﬁcation of
SLE as set out by the American College of
Rheumatology (ACR).16,17
UK JSLE Cohort
A national UK JSLE observational cohort study was
commenced in 2006, and to date over 400 patients
have been enrolled. Almost all UK centres (n¼ 21)
treating patients diagnosed with JSLE participate.
Detailed clinical phenotypic data are obtained at
baseline. Patients are included who are diagnosed
prior to the age of 17 years old. The entire cohort
includes patients meeting two or more ACR classiﬁ-
cation criteria, but for the purpose of this report, we
have included only those who have accrued four or
more ACR criteria by the time of latest follow-
up.16,17 Along with baseline and annual visits, pheno-
typic data are collected at the time of patients’ routine
clinical follow-up. Data are collected prospectively in
a central database at the University of Liverpool.
UCLH SLE juvenile and adult cohort
UCLH is a large multi-racial UK tertiary referral
centre for SLE. A common database established
from patient interviews and chart reviews was cre-
ated and data have been prospectively entered once
four or more ACR criteria were present.
Information from 636 patients in this cohort was
included in this study. A third of patients are from
the hospital’s catchment area, a third from Greater
London and a third from the wider UK.
Combination of two large cohorts
The authors had access to both databases (MWBand
DI, respectively). As it was possible for patients to be
enrolled in both studies, all duplicates were removed
at the point of merging. A core dataset reﬂecting vari-
ables collected across both cohorts was created.
A total of 924 individuals diagnosed with SLE
and meeting 4 ACR criteria were included once
duplicates had been removed. As well as
disaggregated ACR criteria, cardiovascular events
(any event deemed by the treating physician to be a
cardiovascular event such as a myocardial infarct)
and all-cause mortality data were compared between
cohorts.
Information regarding patients that had been col-
lected on both databases (n¼ 24)was used as a tool to
validate recorded information between the cohorts.
The following diﬀerences between the cohorts
were noted: (1) UK JSLE study median follow-up
was 3.7 years; UCLH median follow-up was 15
years. (2) NPSLE was deﬁned as per ACR guide-
lines18 but headaches were not included in the
UCLH cohort as it was deemed that they were pre-
sent almost universally over long-term follow-up of
such a group; therefore headaches were excluded.3
Ethnicity recording varied across cohorts, reﬂecting
in part, changing terminology over time. Broad
classiﬁcations of White, Black, Asian (including
South Asian and Chinese) or Other were adopted.
Age definitions
JSLE was deﬁned for this combined study as SLE
with onset before the patient’s 18th birthday. This
group was further subdivided. Childhood onset was
deﬁned as onset before the 12th birthday and
adolescent onset was deﬁned as those patients diag-
nosed between the ages of 12 and 17 years.
Adult-onset SLE was deﬁned as those patients 18
years or older at the time of diagnosis. This group
was further subdivided. Adults of 18–49 years at
time of diagnosis were described as adult onset.
Patients 50 years or older at time of onset were
deﬁned as the mature-onset group.
Serology
Serological results were recorded as follow: the
presence or absence of persistent hypocomplemen-
temia (C3); antinuclear antibody (ANA) positivity
(measured with Hep2 cells with a cut-oﬀ of> 1:80);
anti-double-stranded DNA (anti-dsDNA) antibody
positivity (over twice the upper limit of normal by
commercial enzyme-linked immunosorbent assay
(ELISA) or a positive crithidia, on two occasions),
anti-extractable nuclear antigen (anti-ENA) posi-
tivity (Ro, La, Sm, and ribonuclear proteins
(RNP), by commercial ELISA). All laboratory
tests were performed in the patient’s local centre
as part of routine clinical care.
Data analysis
Data were analysed by univariable and multivari-
able analysis for demographic, renal biopsy,
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serological and clinical data. Signiﬁcance testing
between groups was performed by Chi square test-
ing across patient characteristics. Mortality rates
were calculated using direct standardization meth-
ods. Individual year population mortality data
from 1901 until 2013 were retrieved from the
Oﬃce for National Statistics Summary Reports.19
Age, gender and calendar year standardized mor-
tality ratios (SMRs) were calculated with a 90%
conﬁdence interval (CI) for the cohorts. Mortality
rates for each decade (based upon year of diagno-
sis) were calculated, and Cuzick’s test for trend was
used to determine signiﬁcance. All analyses were
conducted in Stata (v14).
Results
A total of 924 individuals diagnosed with SLE and
meeting 4 ACR revised criteria were compared,
comprising 413 JSLE (0–17 years at diagnosis) and
511 adult-onset SLE patients (18 years).
Demographics
Demographics of the cohort are shown in Table 1.
A female preponderance was present but less extreme
at either end of the age spectrum. There were signiﬁ-
cantly more male patients (17% vs 8%; p< 0.01) in
the JSLE population compared with the adult popu-
lation. Overall the ratio of female to males (F:M) was
6:1 in JSLE, 5:1 in younger ages, and 7:1 in older
children. Adults had a ratio of 13:1 and 11:1 in the
mature-onset group. It was observed that although
the overall F:M ratio of the mature-onset SLE group
remained high at 11:1; the ratio for patients diag-
nosed from the age of 60 dropped to 3:1. Older
patents were more likely to be White, and higher
percentages of patients of Asian ethnicity were
found within the JSLE population (p< 0.01).
Clinical manifestations at different ages
Table 2 presents the ACR clinical characteristics
(non-renal, non-NPSLE manifestations) between
cohorts. No signiﬁcant diﬀerences were observed
in percentages of patients with a lupus rash between
any groups. Rashes were common both in juvenile
and adult lupus. There was also no diﬀerence in
prevalence of photosensitivity. JSLE patients were
more likely to report alopecia with a clear reduction
of patients reporting alopecia with advancing age.
JSLE patients also reported higher rates of
oral ulcers. Adults were signiﬁcantly more likely
to report arthritis and serositis. There was a non-
statistically signiﬁcant reduction in serositis in the
mature group.
Renal manifestations
JSLE was associated with a signiﬁcantly higher
prevalence of lupus nephritis (44% vs 33%,
p¼ 0.001) (Figure 1). Thirty-one per cent of JSLE
patients had biopsy-proven lupus nephritis com-
pared with 27% of adult-onset SLE patients. In
these patients the median disease duration at the
time of ﬁrst renal biopsy was two months in
JSLE patients and 24 months in adult-onset SLE.
There was no diﬀerence in subtypes of renal neph-
ritis, with diﬀuse proliferative glomerulonephritis
the most common subtype in both groups.
NPSLE
Mature-onset SLE patients were far less likely to
have NPSLE than any other group (Figure 2). We
did not ﬁnd a statistically signiﬁcant diﬀerence
between JSLE and adult SLE NP involvement
but there was a trend towards the JSLE cohort
having more neurological disease.
Haematological and immunological manifestations
Table 3 shows the laboratory characteristics across
the cohorts. Laboratory results were available for all
participants. Lymphopenia was more prevalent with
increasing age. Thrombocytopenia and haemolytic
anaemia were both signiﬁcantly more prevalent in
the JSLE group. Overall the JSLE group was signiﬁ-
cantly more likely to have ‘ACR haematological
involvement’ than adult-onset disease.
ANA was positive in over 94% of patients in all
groups. The JSLE group had a signiﬁcantly higher
prevalence of immunological ﬁndings including
positive anti-dsDNA antibodies, anti-RNP and
anti-Sm autoantibodies. Low complement C3 was
also more prevalent in the JSLE group.
Table 1 Demographic data of the whole SLE cohort
Characteristic All JSLE Childhood Adolescent All adult Adult Mature
Numbers 413 136 277 511 467 44
Female:Male 6:1 5:1 7:1 13:1 13:1 11:1
Median age 13 10 14 31 30 54
Ethnicity (%)
White 50 45 53 60 58 84
Asian 25 31 28 10 14 4
Black 25 21 17 25 26 9
Patients grouped by age of diagnosis: All JSLE 18 years;
Childhood 12 years; Adolescent¼ 12–17 years; All adult¼ 18 years or
older; Adult¼ 18–48 years; Mature¼ 50 years or older. SLE: systemic
lupus erythematosus; JSLE: juvenile systemic lupus erythematosus.
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Cardiovascular events
In total, 12 cardiovascular events were recorded in
JSLE patients (3%) with a median age at event of
16 years and median disease duration two years. In
contrast, 47 events were recorded in the adult
cohort (9%), with a median age at event 47 years
and median disease duration 10 years.
Mortality
Of the 882 patients with suﬃcient long-term infor-
mation (patients who had moved away or were lost
to follow-up were excluded), 95 deaths occurred
during follow-up. The overall mortality rate in the
JSLE group was 0.5/100 patient years (pyrs) (95%
CI 0.3 to 0.9) and in the adult SLE group was
Figure 1 Breakdown of renal involvement by age. The left-hand bars show the breakdown by age as divided into four groups. The
right-hand bars summarize key differences between JSLE and adult SLE groups.
JSLE: juvenile systemic lupus erythematosus; SLE: systemic lupus erythematosus.
Figure 2 Breakdown of CNS lupus by age. The left-hand bars show the breakdown by age as divided into four groups. The right-
hand bars summarize key differences between JSLE and all-adult SLE groups.
CNS: central nervous system; JSLE: juvenile systemic lupus erythematosus; SLE: systemic lupus erythematosus.
Table 2 General clinical characteristics of the whole SLE cohort (% of whole SLE cohort)
Characteristic All JSLE Childhood Adolescent All adult Adult Mature Significance (p)
Rash 60 70 70 67 68 52 0.362
Photosensitivity 34 33 35 41 42 30 0.057
Alopecia 47 48 46 23 24 18 <0.001
Oral ulcers 39 35 41 26 26 32 <0.001
Joint 72 66 75 93 93 98 <0.001
Serositis 23 18 26 41 43 27 <0.001
Data displayed as percentages of the whole group. Patients grouped by age of diagnosis: All JSLE 18 years; Childhood 12 years;
Adolescent¼ 12–17 years; All adult¼ 18 years or older; Adult¼ 18–48 years; Mature¼ 50 years or older. Significance (p)¼ comparison of All
JSLE to All adult SLE patients. SLE: systemic lupus erythematosus; JSLE: juvenile systemic lupus erythematosus.
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10.7/100 pyrs (95% CI 0.8 to 13.5). Mortality rates
by age of onset declined over the decades: 1950: 2.5/
100 pyrs (CI 0.6 to 10.1); 2000: 0.4 (CI 0.2 to 0.7)
(Figure 3(a)). The trend in changing mortality was
statistically signiﬁcant (p¼ 0.019).
When standardized to the expected mortality rates
of the general population, the JSLE group was found
to have an SMR of 18.3 (CI 11.8 to 28.3) and the
adult SLE group 3.1 (CI 2.6 to 3.9). The age-speciﬁc
mortality rates are shown in Figure 3(b). The SMR
in the 0–9 age group was particularly elevated at 87
(CI 27 to 292); therefore, this group was excluded
from the graphic (Figure 3(b)) to enable appreciation
of the other SMRs. A non-statistically signiﬁcant
trend was seen towards higher mortality rates
amongst the female population.
Discussion
Comparison of SLE phenotype by age group in two
large UK cohorts revealed similarities, but also
important diﬀerences between the age groups.
Previous studies have suggested disease to be
more severe in the juvenile population, with a
milder course in mature onset, and our results
strongly support this.4,11–13,15,20–26 Importantly we
identiﬁed that young age is a critical factor in SMR.
As with other studies we found a female predom-
inance that was less pronounced at both ends of the
age spectrum. In adults the female:male ratio was
13:1, which is higher than some groups report.
Compared to other studies mostly based in North
America,27 our data showed a low percentage of
non-Whites. Older patents were even more likely
to be White with higher percentages of patients of
Asian ethnicity within the JSLE population. There
are very few large studies speciﬁcally looking at
mature-onset SLE. Available studies report an inci-
dence of 12–20% of adult-onset SLE.7–9,28–30
Overall 5% of our patients were mature at onset,
or 9% of the whole adult-onset population.
No diﬀerence was observed in the prevalence of a
lupus rash between any groups. Others have reported
that a malar rash may be more frequent in chil-
dren5,21,24,31,32 and that a discoid rash is more
common in adults.5 We did not diﬀerentiate between
discoid and malar rash. JSLE was also associated with
more frequently reported alopecia with a clear reduc-
tion of alopecia with advancing age. A meta-analysis
of mature-onset SLE patients has also reported a
lower prevalence of alopecia.7 We found that arthritis
increased with advancing age, which is in agreement
with some studies8,15,22 but not with others.9,28,30,32
Serositis was more common in adult-onset
than juvenile-onset disease, although we did note
a non-statistically signiﬁcant drop-oﬀ of this ﬁnd-
ing in the mature-onset group. Some literature
agrees9,30 with this observation, but other studies
have found more serositis in the older age group.8
Further studies speciﬁcally addressing this with
large cohorts of older patients are required.
Table 3 Haematological and immunological involvement (% of the whole SLE cohort)
All JSLE Childhood Adolescent All adult Adult Mature Significance (p)
Haematological
Lymphopenia 62 51 68 76 75 84 <0.001
Leucopenia 32 29 34 30 31 25 0.590
Thrombocytopenia 21 19 22 15 15 16 0.011
Haemolytic anaemia 20 24 19 3 3 0 <0.001
Coombs positive 24 24 23 21 21 16 0.350
ACR ‘haematological’ 0.046
Immunological
ANA 97 98 97 94 94 95 0.061
dsDNA 71 75 69 63 63 57 0.009
Low C3 62 57 65 46 48 23 <0.001
Sm 22 19 23 16 17 7 0.021
RNP 36 33 37 29 30 18 0.038
Ro 35 30 37 38 40 23 0.335
La 17 13 18 15 15 14 0.450
ACR ‘immunological’ 0.075
Data displayed as percentages of the whole group. Patients grouped by age of diagnosis: All JSLE 18 years; Childhood 12 years;
Adolescent¼ 12–17 years; All adult¼ 18 years or older; Adult¼ 18–48 years; Mature¼ 50 years or older. Significance (p)¼ comparison of All
JSLE to All adult SLE patients. ACR ‘haematological’¼ any haematological involvement by ACR criteria. ACR ‘immunological’: any immuno-
logical involvement by ACR criteria; SLE: systemic lupus erythematosus; JSLE: juvenile systemic lupus erythematosus; ACR: American College of
Rheumatology; ANA: antinuclear antibodies; dsDNA: double-stranded DNA.
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JSLE was associated with more frequent lupus
nephritis whereas nephritis was uncommon in
mature-onset SLE. Other studies have consistently
shown more frequent renal involvement in
JSLE,12,15,21,23,25,32 and indeed groups have shown
that JSLE is a risk factor for progression to dialysis.33
Studies looking atmature-onset SLEhave found renal
involvement to be less common in that age group.9
We found that mature-onset SLE patients were
far less likely to have NPSLE disease than any
other group. Previous studies including two meta-
analyses of mature-onset SLE cohort data are in
agreement with this.7,9,32 Interestingly, we did not
ﬁnd a statistical diﬀerence in prevalence between
juvenile-onset and adult-onset NPSLE, despite pre-
vious reports suggesting NPSLE involvement may
Figure 3 (a) Mortality rate expressed per 100 patient years, by decade of diagnosis of SLE, showing a reduction of mortality rates
over time. (b) Standardized mortality ratio (SMR) of entire cohort by age, grouped into decades, with 90% confidence intervals.
Deaths: deaths per 100 patient years; Expected: expected deaths per 100 in England and Wales population; Lower: 90% lower
confidence interval; Upper: 90% upper confidence interval; SLE: systemic lupus erythematosus.
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be more common in JSLE.12,15,31 There was a trend
towards the JSLE cohort having more neurological
disease. Other groups have subanalysed their data
and have found JSLE to be associated with seiz-
ures,22,24 and one study reported that older age
was associated with more peripheral neuropa-
thies.31 Previous reports have used methods that
have varied widely with some groups having
narrow deﬁnitions of NPSLE as psychosis or seiz-
ures (ACR criteria) or others using the updated
ACR criteria, which even include headaches. We
had chosen not to classify headaches as NPSLE,
in order to capture the more severe end of the
neurological spectrum.
We found lymphopenia to be more prevalent
with increasing age whereas JSLE was associated
with thrombocytopenia and haemolytic anaemia.
Haematological manifestations in JSLE have been
described to include leucopenia, thrombocytopenia
and haemolytic anaemia.5,12,15,24,32 The JSLE
group had a higher prevalence of immunological
involvement including anti-dsDNA, anti-RNP
and anti-Sm autoantibodies. JSLE was also asso-
ciated with low complement C3. These ﬁndings
were in keeping with other studies.15,20,32
Autoantibodies were less common in mature-
onset SLE, also in keeping with other studies.9,32
The mortality ﬁndings were highly signiﬁcant.
We found that the entire cohort had an increased
SMR, although the magnitude of diﬀerence was far
more striking in the JSLE population, with an
SMR amongst children under 10 of 87 (CI 27 to
292). The SMR remained increased throughout the
age groups, although the magnitude diminished
with increasing age. Our group has previously
reported a high SMR (with wide CIs) in the
UCLH cohort.13 This updated analysis has utilized
a larger sample size. Our data highlight the signiﬁ-
cantly increased risk when standardized against the
background population which is most pronounced
in the youngest population. These data are consist-
ent both with our own group’s previous ﬁndings
and also with other studies from North
America.34 A study from Washington published a
life-type survival curve which showed no diﬀerence
over ﬁve years between the groups, but the expect-
ation would have been that few if any adolescents
should have died. This study did not calculate
SMRs.34 The trans-American Lupus in
Minorities: Nature versus Nurture (LUMINA)
trial published mortality ﬁgures within their
group, by age. They found high numbers of
deaths in patients of African American descent in
the JSLE group. They reported 11 deaths (six
adolescent and ﬁve adults) out of a total of 79
patients. These results are far in excess of rates
expected.12
Our results ﬁnd that survival has improved over
the decades within the cohort. This is consistent
with existing publications that report in the adoles-
cent population 10-year survival has improved
from 78% in the 1970s to 94% to 100% in 2000s.
This may reﬂect patients being cared for in dedi-
cated units, or increased recognition of the disease
and hence earlier diagnosis or milder cases being
identiﬁed and referred. Groups studying children
not under specialist care continue to report higher
risk, which appears to relate to socioeconomic
status.12
Our study has some limitations. We compared
two distinct cohorts, which required trimming of
datasets to the common information collected by
both groups. We are aware of potential selection
bias at UCLH, which is a tertiary referral centre,
which may skew our adult results to suggest serious
manifestations are commoner than if we captured
the whole SLE population. Therefore, results indi-
cating higher rates in children (e.g. lupus nephritis)
may in reality be higher yet, and a lack of diﬀerence
(e.g. NPSLE) may miss a real diﬀerence. The two
cohorts had signiﬁcantly diﬀerent median lengths
of follow-up, thus deﬁnite conclusions of long-
term damage were beyond the scope of this paper.
We are unable to comment on likely diﬀerences in
cardiovascular complications between the two
groups, as the median ‘event’ occurred at 10 years
in the adult cohort, which is longer than the current
follow-up of the JSLE cohort.
This study signiﬁcantly contributes to the current
knowledge of SLE phenotypes. It is the ﬁrst large
cohort to look at SLE via the whole age spectrum.
The reasons why a phenotype diﬀers depending on
age of onset remains a matter of conjecture. SLE is a
multifactorial condition and those presenting at a
younger age may be more likely to have more genetic
contributions and diﬀerences in hormone levels, such
as oestrogen.5 These data conﬁrm an aggressive
phenotype of disease in patients with onset of SLE in
childhood and adolescence and supports the need for
intensive follow-up and therapy in this population.
Key messages
1. Systemic lupus erythematosus (SLE) is a severe
chronic disease that may present at any age and
in either gender. Clinical manifestations are simi-
lar at all ages but incidence and severity diﬀer.
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2. SLE confers an increased standardized mortality
ratio, which is particularly pronounced in
younger patients.
3. Mature-onset SLE may have a more benign
phenotype but with more arthritis.
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